Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation

(2011) L. Wang et al.   SCIENCE

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

Transforming activity of AML1-ETO is independent of CBFβ and ETO interaction but requires formation of homo-oligomeric complexes

(2009) Colin Kwok et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis

(2008) M. Yan et al.   BLOOD

AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain

(2008) Hui Wei et al.   FEBS LETTERS

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

(2008) R. G.W. Verhaak et al.   HAEMATOLOGICA

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

(2008) J A McCubrey et al.   LEUKEMIA

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets

(2008) Alessandro Gardini et al.   PLoS Genetics